We focus on research and development of innovative technologies and breakthrough therapies for unmet medical needs and orphan diseases.
a new biotech for neurological disorders
The development of the lead products CRES101 ans CRES102 for the treatments of neurodegenerative diseases strengthens the offert of innovative therapeutic solutions.
We are an agile corporate structure of Directors and Scientific Advisors.
Our commitment is to turn our efforts into research, with passion, competence and boldness.
Prof. Giuseppe Scalabrino